$9.39
1.73% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US24661P5008
Symbol
DCTH

Delcath Systems Inc Stock price

$9.39
+0.46 5.15% 1M
+2.20 30.60% 6M
+5.23 125.72% YTD
+7.03 297.88% 1Y
-1.11 10.57% 3Y
-21.41 69.51% 5Y
-2,802,799,990.61 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.16 1.73%
ISIN
US24661P5008
Symbol
DCTH
Sector

Key metrics

Market capitalization $262.93m
Enterprise Value $252.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.13
P/S ratio (TTM) P/S ratio 11.61
P/B ratio (TTM) P/B ratio 30.70
Revenue growth (TTM) Revenue growth 945.91%
Revenue (TTM) Revenue $22.64m
EBIT (operating result TTM) EBIT $-26.75m
Free Cash Flow (TTM) Free Cash Flow $-26.20m
Cash position $13.99m
EPS (TTM) EPS $-1.36
P/E forward negative
P/S forward 7.49
EV/Sales forward 7.17
Short interest 4.46%
Show more

Is Delcath Systems Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Delcath Systems Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Delcath Systems Inc forecast:

6x Buy
100%

Analyst Opinions

6 Analysts have issued a Delcath Systems Inc forecast:

Buy
100%

Financial data from Delcath Systems Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
23 23
943% 943%
100%
- Direct Costs 4.27 4.27
259% 259%
19%
18 18
1,774% 1,774%
81%
- Selling and Administrative Expenses 29 29
62% 62%
129%
- Research and Development Expense 16 16
9% 9%
69%
-26 -26
23% 23%
-117%
- Depreciation and Amortization 0.30 0.30
39% 39%
1%
EBIT (Operating Income) EBIT -27 -27
23% 23%
-118%
Net Profit -34 -34
24% 24%
-151%

In millions USD.

Don't miss a Thing! We will send you all news about Delcath Systems Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Delcath Systems Inc Stock News

Neutral
Seeking Alpha
7 days ago
Delcath Systems Inc (NASDAQ:DCTH ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, Interventional Oncology Vojislav Vukovic - Chief Medical Officer Conference Call Participants Sudan Loganathan - Stephen...
Neutral
Business Wire
8 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the third quarter ended September 30, 2024. Third Quarter and Recent Business Highlights Total third quarter revenues of $11.2...
Neutral
Business Wire
14 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences: Stephens Biotechnology Virtual Fireside Chats Date: Wednesday, November 13, 2024 Fireside Chat Time: 9:30 am Eastern Time...
More Delcath Systems Inc News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Head office United States
CEO Gerard Michel
Employees 76
Founded 1988
Website www.delcath.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today